Low- Dose Propofol Infusion as an Abortive Treatment for Migraine Headaches in Pediatric Patients
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Propofol has been used in adult populations to treat migraines as an abortive agent.
Investigators plan to investigate its efficacy as an abortive agent in the pediatric
population when administered as a safe low-dose infusion. Goals of the study are to:
1. Evaluate efficacy of low-dose propofol infusion as an abortive agent in pediatric
migraine headaches
2. Evaluate effective and safe dosing limits in pediatric populations
3. Evaluate duration of effect reached from a low-dose propofol infusion as an abortive
agent
Endpoints for the study will be:
1. Number of enrolled patients
2. Safety endpoints reached, including: cardiopulmonary depression, excessive somnolence
Risks of the study are minimal due to the use of sub-anesthetic dosing of propofol under
the guidance and supervision of a board certified pediatric anesthesiologist with the
appropriate monitoring equipment and readily available emergency equipment.
Investigators hope to demonstrate more rapid improvement and decreased side-effect as
compared to standard care.